EMC2

Across TCGA pan-cancer cohorts, EMC2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EMC2 data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher EMC2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EMC2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

OV, CCRCC, and LSCC are the cancer types where EMC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.867	1.000	.049	8	view →
CCRCC	DFS	Tertile	III,IV	0.347	0.685	.007	8	view →
LSCC	DFS	Quartile	II,III,IV	0.931	0.661	.009	8	view →
HNSC	DFS	Median	II,III,IV	0.776	0.545	.009	6	view →
LUAD	DFS	Tertile	All	0.507	0.895	.009	4	view →
PDAC	DFS	Tertile	All	0.222	0.400	.035	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EMC2–OV (DFS)

Open the OV breakdown →